Corbus Pharmaceuticals Holdings Inc Stock Research

Market Summary

USD6.85+0.39

Market Closed

6.04%

CRBP Stock Price

CRBP RSI Chart

CRBP Valuation

Market Cap

28.6M

Price/Earnings (Trailing)

-0.67

Price/Sales (Trailing)

19.11

Price/Free Cashflow

-0.76

CRBP Price/Sales (Trailing)

CRBP Profitability

Return on Equity

-128.36%

Return on Assets

-63.86%

Free Cashflow Yield

-131.44%

CRBP Fundamentals

CRBP Revenue

CRBP Earnings

Earnings (TTM)

-42.3M

Earnings Y/Y

-6.03%

Earnings Q/Q

-23.88%

Price Action

52 Week Range

0.108.10

(Low)(High)

Last 7 days

19.1%

Last 30 days

145.5%

Last 90 days

5656.3%

Trailing 12 Months

1270%

CRBP Financial Health

Current Ratio

4.76

Debt/Equity

0.64

Debt/Cashflow

-1.77

CRBP Investor Care

Buy Backs (1Y)

0.07%

Diluted EPS (TTM)

-10.15

Peers (Alternatives to Corbus Pharmaceuticals Holdings)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	298.0B	1.4B	-3.25%	8.54%	-148.7	210.43	20.37%	-37.45%
ABBV	279.9B	58.1B	4.88%	1.38%	23.64	4.82	3.30%	2.55%
REGN	87.7B	12.2B	9.61%	20.63%	20.21	7.2	-24.26%	-46.28%
VRTX	80.8B	8.9B	6.80%	24.91%	24.32	9.05	17.91%	41.84%
ALNY	23.5B	1.0B	-5.53%	16.05%	-20.81	22.69	22.88%	-32.64%
SRPT	11.5B	933.0M	2.93%	61.85%	-16.28	12.27	32.93%	-67.99%
UTHR	10.1B	1.9B	-9.77%	22.96%	13.92	5.23	14.88%	52.86%
MID-CAP
MDGL	4.2B	504.0K	-19.59%	144.55%	-14.38	2.5K	-66.53%	-22.12%
RARE	2.6B	363.3M	-18.37%	-45.49%	-3.74	7.28	3.39%	-55.81%
BPMC	2.6B	204.0M	1.49%	-34.21%	-4.68	12.78	13.30%	13.44%
MRTX	2.3B	12.4M	-15.06%	-52.42%	-3.05	181.9	-	-27.34%
SMALL-CAP
CPRX	1.7B	214.2M	4.81%	93.98%	20.42	7.92	52.10%	110.42%
MGNX	412.2M	151.9M	1.98%	-27.23%	-3.44	2.71	96.19%	40.75%
CRBP	28.6M	-	145.52%	1270.00%	-0.67	19.11	-77.61%	7.22%
CYTK	3.1M	94.6M	-20.08%	-11.44%	-0.01	0.03	34.30%	-80.65%

Financials for Corbus Pharmaceuticals Holdings

* denotes actual numbers (not divided by Thousands)
Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q4	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-100.0%		882	1,540	2,673	2,823
Operating Expenses	-30.0%	39,835	56,871	-	-	-
S&GA Expenses	13.9%	18,699	16,417	-	-	-
R&D Expenses	-48.0%	16,137	31,062	-	-	-
Interest Expenses	13.6%	-1,830	-2,119	-	-	-
Net Income	7.2%	-42,346	-45,640	-	-	-
Free Cahsflow	-	-37,557	-	-	-	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-10.2%	66.00	74.00	82.00	96.00	108
Current Assets	-10.6%	60.00	67.00	75.00	88.00	100
Cash Equivalents	36.6%	17.00	12.00	26.00	57.00	25.00
Net PPE	-10.3%	2.00	2.00	2.00	2.00	2.00
Liabilities	4.5%	33.00	32.00	33.00	35.00	39.00
Current Liabilities	-27.6%	13.00	17.00	16.00	15.00	17.00
Long Term Debt	0%	21.00	21.00	21.00	21.00	-
LT Debt, Current	32.2%	10.00	7.00	5.00	3.00	-
LT Debt, Non Current	70.3%	16.00	9.00	12.00	14.00	16.00
Shareholder's Equity	-21.4%	33.00	42.00	49.00	61.00	69.00
Retained Earnings	-2.9%	-392	-381	-372	-359	-349
Additional Paid-In Capital	0.4%	425	423	422	420	419
Accumulated Depreciation	7.0%	3.00	3.00	3.00	2.00	-
Shares Outstanding	-0.1%	4.00	4.00	4.00	4.00	4.00
Float	-	202	-	-	-	-

* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	5.6%	-37.54	-39.79	-31.69	-36.99	-48.18
Share Based Compensation	-8.4%	6.00	6.00	7.00	8.00	9.00
Cashflow From Investing	98.9%	30.00	15.00	21.00	27.00	-73.42
Cashflow From Financing	-53361600.0%	-0.53	1*	0.00	0.00	61.00

Risks for CRBP

What is the probability of a big loss on CRBP?

100%

Probability that Corbus Pharmaceuticals Holdings stock will be more than 20% underwater in next one year

100%

Probability that Corbus Pharmaceuticals Holdings stock will be more than 30% underwater in next one year.

85.4%

Probability that Corbus Pharmaceuticals Holdings stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRBP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Corbus Pharmaceuticals Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for CRBP

Cumulative Returns on CRBP

20.5%

7-Year Cumulative Returns

1.9%

5-Year Cumulative Returns

13.0%

3-Year Cumulative Returns

What are the long-term rolling returns for CRBP?

FIve years rolling returns for Corbus Pharmaceuticals Holdings.

Annualized Returns

Which funds bought or sold CRBP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-15	B. Riley Wealth Advisors, Inc.	new	-	2,365	2,365	-%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	sold off	-100	-	-	-%
2023-02-14	BOOTHBAY FUND MANAGEMENT, LLC	unchanged	-	-2,587	4,413	-%
2023-02-14	Knoll Capital Management, LLC	sold off	-100	-833,000	-	-%
2023-02-14	Bank of New York Mellon Corp	reduced	-6.53	-1,457	3,543	-%
2023-02-14	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	68.75	2,394	17,394	-%
2023-02-14	TWO SIGMA SECURITIES, LLC	new	-	9,339	9,339	-%
2023-02-14	Verition Fund Management LLC	sold off	-100	-22,000	-	-%
2023-02-14	TWO SIGMA ADVISERS, LP	sold off	-100	-3,000	-	-%
2023-02-14	TWO SIGMA INVESTMENTS, LP	added	366	43,004	63,004	-%

Latest Funds Activity

Are funds buying CRBP calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own CRBP

No. of Funds

Corbus Pharmaceuticals Holdings News

Schedule 13G FIlings of Corbus Pharmaceuticals Holdings

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Aug 24, 2022	etf managers group, llc	4.95%	6,194,679	SC 13G/A
Feb 14, 2022	etf managers group, llc	8.78%	10,995,143	SC 13G/A
Jun 01, 2021	etf managers group, llc	11.39%	14,240,357	SC 13G/A
May 11, 2021	etf managers group, llc	5.34%	6,673,458	SC 13G/A
Apr 12, 2021	blackrock inc.	4.5%	5,673,664	SC 13G/A
Mar 17, 2021	etf managers group, llc	4.80%	5,997,343	SC 13G/A
Feb 16, 2021	etf managers group, llc	6.96%	5,851,347	SC 13G/A
Feb 12, 2021	etf managers group, llc	9.28%	7,796,166	SC 13G/A
Jan 29, 2021	blackrock inc.	6.2%	5,220,525	SC 13G/A
Jan 11, 2021	state street corp	1.59%	1,333,546	SC 13G/A

CRBP Fair Value

Corbus Pharmaceuticals Holdings fair value in different scenarios

The table shows the Fair Value estimates for Corbus Pharmaceuticals Holdings for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	1.80 -73.72%	1.90 -72.26%	2.19 -68.03%	2.64 -61.46%	3.81 -44.38%
Current Inflation	1.79 -73.87%	1.89 -72.41%	2.15 -68.61%	2.54 -62.92%	3.56 -48.03%
Very High Inflation	1.79 -73.87%	1.87 -72.70%	2.09 -69.49%	2.42 -64.67%	3.26 -52.41%

Historical Corbus Pharmaceuticals Holdings Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Corbus Pharmaceuticals Holdings

View All Filings

Date Filed	Form Type	Document
Mar 10, 2023	S-8	Employee Benefits Plan
Mar 07, 2023	8-K	Current Report
Mar 07, 2023	4	Insider Trading
Mar 07, 2023	3	Insider Trading
Mar 07, 2023	10-K	Annual Report
Mar 06, 2023	8-K	Current Report
Feb 15, 2023	8-K/A	Current Report
Feb 15, 2023	4	Insider Trading
Feb 15, 2023	4	Insider Trading
Feb 15, 2023	4	Insider Trading

Latest Insider Trading transactions for CRBP

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-08-10	Cohen Yuval	bought	1,003	0.264	3,800	chief executive officer
2022-08-10	Millian Craig Stuart	bought	1,272	0.2545	5,000	chief operating officer
2022-08-10	Moran Sean F.	bought	5,198	0.2599	20,000	chief financial officer
2022-05-16	Cohen Yuval	bought	2,625	0.25	10,500	chief executive officer
2022-05-16	Moran Sean F.	bought	3,600	0.3	12,000	chief financial officer
2022-03-10	Millian Craig Stuart	bought	3,700	0.37	10,000	chief operating officer
2022-03-10	Moran Sean F.	bought	5,550	0.37	15,000	chief financial officer
2022-03-09	Cohen Yuval	bought	3,182	0.37	8,600	chief executive officer
2020-12-21	Moran Sean F.	acquired	122,500	1.4	87,500	chief financial officer
2020-12-21	Moran Sean F.	sold	-153,125	1.75	-87,500	chief financial officer

About Corbus Pharmaceuticals Holdings

Yuval Cohen

www.corbuspharma.com

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ÃƒÅ¸ (TGFÃƒÅ¸); and CRB-602, an anti-avÃƒÅ¸6/avÃƒÅ¸8 mAb that blocks the activation of TGFÃƒÅ¸ for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue from awards	$ 0	$ 881,705
Operating expenses:
Research and development	16,136,826	36,445,285
General and administrative	18,698,619	20,425,444
Litigation Settlement	5,000,000	0
Total operating expenses	39,835,445	56,870,729
Operating loss	(39,835,445)	(55,989,024)
Other income (expense), net:
Other income (expense), net	(48,773)	11,899,992
Interest income (expense), net	(2,132,091)	(1,830,486)
Change in fair value of derivative liability	96,842	663,290
Foreign currency exchange gain (loss), net	(427,436)	(384,198)
Other income (expense), net	(2,511,458)	10,348,598
Net loss	$ (42,346,903)	$ (45,640,426)
Net loss per share, basic	$ (10.15)	$ (11.15)
Net loss per share, diluted	$ (10.15)	$ (11.15)
Weighted average number of common shares outstanding, basic	4,170,675	4,094,935
Weighted average number of common shares outstanding, diluted	4,170,675	4,094,935
Comprehensive loss:
Net loss	$ (42,346,903)	$ (45,640,426)
Other comprehensive income (loss):
Change in unrealized gain (loss) on marketable debt securities	(63,647)	(62,445)
Total other comprehensive income (loss)	(63,647)	(62,445)
Total comprehensive loss	$ (42,410,550)	$ (45,702,871)

CRBP Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 17,002,715	$ 25,006,632
Investments	42,194,296	72,640,520
Restricted cash	192,475	192,475
Prepaid expenses and other current assets	791,616	2,365,010
Total current assets	60,181,102	100,204,637
Restricted cash	477,425	477,425
Property and equipment, net	1,613,815	2,392,696
Operating lease right of use assets	3,884,252	4,609,110
Other assets	155,346	46,385
Total assets	66,311,940	107,730,253
Current liabilities:
Notes payable	353,323	767,938
Accounts payable	2,173,963	1,782,277
Accrued expenses	5,999,252	10,093,312
Derivative liability	36,868	133,710
Operating lease liabilities, current	1,280,863	1,136,948
Current portion of long-term debt	2,795,669	3,093,344
Total current liabilities	12,639,938	17,007,529
Long-term debt, net of debt discount	15,984,426	15,636,275
Other long-term liabilities	22,205	22,205
Operating lease liabilities, noncurrent	4,675,354	5,956,217
Total liabilities	33,321,923	38,622,226
Stockholders' equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and December 31, 2021. See Note 13	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized, 4,171,297 and 4,169,631 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	417	416
Additional paid-in capital	425,196,359	418,903,820
Accumulated deficit	(392,080,667)	(349,733,764)
Accumulated other comprehensive loss	(126,092)	(62,445)
Total stockholders’ equity	32,990,017	69,108,027
Total liabilities and stockholders’ equity	$ 66,311,940	$ 107,730,253